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Objectives The purpose of this study was to perform a systematic review and meta-analysis of prospective randomized clini-
cal trials of cardiac resynchronization therapy (CRT) versus implantable cardioverter-defibrillator (ICD) in patients
with reduced ejection fraction (EF), prolonged QRS interval, and New York Heart Association (NYHA) functional
class I to II heart failure (HF).
Background In patients with advanced HF, CRT improves left ventricular (LV) function and reduces mortality and hospitaliza-
tions. Recent data suggest that patients with milder HF also benefit from CRT.
Methods A meta-analysis of 5 clinical trials including 4,317 patients with NYHA functional class I/II HF was performed.
Results Average age of patients was 65 years, and 80% were male. Frequency of all-cause mortality for CRT versus ICD
was 8% versus 11.5% (risk ratio [RR]: 0.81; 95% confidence interval [CI]: 0.65 to 0.99, p  0.04); for HF hospi-
talization, it was 11.6% versus 18.2% (RR: 0.68; 95% CI: 0.59 to 0.79, p  0.001). Patients assigned to CRT
had a significantly greater improvement in LVEF (5.9% vs. 2.2%, p  0.001) and LV volume than ICD pa-
tients. Among mildly symptomatic (NYHA functional class II) patients, CRT was associated with significantly
lower mortality and HF hospitalization (RR: 0.73; 95% CI: 0.64 to 0.83), p  0.001). In asymptomatic (NYHA
functional class I) patients, HF hospitalization risk was lower (RR: 0.57; 95% CI: 0.34 to 0.97, p  0.04) with
CRT; however, there was no difference in mortality. Twelve asymptomatic HF patients needed to be treated with
CRT to prevent 1 hospitalization.
Conclusions Cardiac resynchronization therapy decreases all-cause mortality, reduces HF hospitalizations, and improves LVEF
in NYHA functional class I/II HF patients. Although there was a reduction in HF hospitalization with CRT for
asymptomatic (NYHA functional class I) patients, risks versus benefits have to be carefully considered in this
subgroup. (J Am Coll Cardiol 2011;58:935–41) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.022n
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tHeart failure (HF) is a major public health problem in the
United States, with an estimated 6 million current patients,
500,000 new patients each year, and an expenditure of $40
billion spent annually for treatment (1). Sudden cardiac death
and worsening HF are the 2 predominant causes of death in
HF patients with left ventricular (LV) dysfunction (2). Over
he last 30 years, there has been a remarkable improvement
n the survival of HF patients due to medical therapies and
he implantable cardioverter-defibrillator (ICD) (3).
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accepted May 24, 2011.Cardiac resynchronization therapy (CRT) has been
oted to improve symptoms and LV systolic function and
educe mortality and hospitalizations among patients
ith moderate to severe HF symptoms, reduced LV
jection fraction (EF), and a wide QRS complex on
lectrocardiogram (4 –9). Recent evidence from random-
zed clinical trials suggests that the salutary effects of
RT on LV morphology, HF symptoms, hospitaliza-
ions, and mortality also extend to patients with mild HF
10 –14). However, pooled analysis of CRT effect on
atients with New York Heart Association (NYHA)
unctional class I and II HF has not been done, and CRT
ffects on subgroups of asymptomatic HF patients has
ot been examined. Indeed, each individual trial included
small number of such patients. Thus, the purpose of the
resent investigation was to perform a systematic review
nd meta-analysis of prospective randomized clinical
rials of CRT in patients with NYHA functional class
/II HF, EF 40%, and QRS 120 ms.
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Data sources and study search
strategy. We identified random-
ized clinical trials published in
MEDLINE from 1960 through
January 2010 using the following
keywords: cardiac resynchroniza-
tion therapy or biventricular pac-
ing. We limited our search criteria
to include studies published in the
English language and those in-
volving humans. We identified ad-
ditional studies by searching the
website www.clinicaltrials.gov and
by hand searching the references
cited in relevant publications. The methodology utilized in this
study has been published previously (15).
Study selection. We included prospective randomized clin-
ical trials that: 1) enrolled asymptomatic or mildly symptomatic
(NYHA functional class I/II) HF patients with EF40% and
QRS duration120 ms; 2) compared CRT versus ICD alone;
and 3) reported mortality, heart failure, hospitalization, and
LV dimensions or volume. In studies that also included
patients with more severe HF, the subset of patients with
NYHA functional class I/II symptoms were included in this
analysis. When data were missing or incomplete, we contacted
the authors/sponsors of the original studies to provide the
necessary information.
Our initial search yielded 3,494 citations (Fig. 1). Of
these, 3,001 were excluded by title search because of
irrelevant content, animal subjects, or publication in a
language other than English. The abstracts of the remaining
493 articles were reviewed. Of these, 473 were excluded
because the study was not a randomized clinical trial (n 
343), it was a duplicate publication (n 22), a retrospective
analysis (n  15), the control group did not get ICDs (n 
34), the outcomes of interest in this meta-analysis were not
reported (n  53); and specific study population was
included (n  6). Of the remaining 20 publications, 15
included patients with NYHA functional class III/IV HF.
The remaining 5 trials were included in the systematic
review (10–14) (Fig. 1).
Data extraction. Data were abstracted by 2 reviewers (S.A.
and H.R.) using standardized data extraction forms. Dis-
crepancies between the reviewers were infrequent and re-
solved by discussion. Abstracted information included study
design, methods, patient characteristics, relevant outcomes,
and adverse events.
Outcomes. The primary outcome for this systematic re-
view was all-cause mortality. Secondary outcomes were HF
events requiring inpatient hospitalization or outpatient
treatment with intravenous medications and parameters of
LV function and size on echocardiography.
Methodological quality. Randomized clinical trials in-
Abbreviations
and Acronyms
CI  confidence interval
CRT  cardiac
resynchronization therapy
EF  ejection fraction
HF  heart failure
ICD  implantable
cardioverter-defibrillator
LV  left ventricular
NYHA  New York Heart
Association
RR  risk ratiocluded in the meta-analysis were evaluated according to theDelphi criteria (16) and scored on the basis of the Jadad
scale (17). Factors considered in methodological quality
included adequacy of randomization method and allocation
concealment, similarity of study groups at baseline, specifi-
cation of eligibility criteria, blinding of the patient, the
clinician, and the outcome assessor, presentation of point
estimates and measures of variability for the outcome
measures, description of withdrawals and dropouts, and
application of intention-to-treat analysis (16,17). Hetero-
geneity among studies was examined with the I2 test (18).
We limited publication bias by using a comprehensive
electronic and hand-search strategy as well as contacting
authors of identified studies.
Data synthesis and statistical analysis. We calculated
weighted mean difference and 95% confidence interval (CI)
for continuous variables, and weighted risk ratios (RRs) and
95% CI for categorical variables. RRs were defined as the
risk of an event for CRT versus ICD alone. Each RR was
calculated according to the DerSimonian-Laird random
effects model. Automatic “zero cell” correction was used for
studies with no events for a particular outcome. The I2
statistic was used to quantify heterogeneity. A value 50%
Figure 1 Selection of Clinical Trials Included
in Systematic Review and Meta-Analysis
ICD  implantable cardioverter-defibrillator; NYHA  New York Heart Association.
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specified subgroup analyses of patients with NYHA func-
tional class II and I symptoms separately were performed.
All comparisons were 2-sided, and a p value 0.05 was
considered statistically significant. All analyses were per-
formed using STATA software, version 10.1 (STATA
Corporation, College Station, Texas).
Results
Study and patient characteristics. The characteristics of
the 5 randomized clinical trials that met eligibility criteria
are displayed in Table 1. All studies included HF patients
with reduced EF, wide QRS interval, and NYHA func-
tional class I or II symptoms, although the entrance criteria
for EF and QRS duration varied slightly between studies
(Table 1). In 2 studies, which also enrolled patients with
more severe HF symptoms (10,14), only the outcomes of
participants with NYHA functional class I/II symptoms
were analyzed in this meta-analysis. Follow-up ranged from
6 to 40 months. In 3 studies (12–14), all participants
underwent LV lead implantation, whereas in 2 studies
(10,11) only patients assigned to CRT had LV leads
Randomized Clinical Trials of CRT Versus ICDTable 1 Randomized Clinical Trials of CRT Versus ICD
Study Acronym (Ref. #) Year N Participants
RAFT (10) 2010 1,798* NYHA II/III heart failure
Left ventricular EF 30%
QRS duration 120 ms
Paced QRS duration 200 ms
CRT
MADIT-CRT (11) 2009 1,820 NYHA I/II heart failure
Left ventricular EF 30%
QRS duration 130 ms
CRT
REVERSE (12) 2008 610 NYHA I/II heart failure
Left ventricular EF 40%
QRS duration 120 ms
LVEDD 55 mm
CRT
MIRACLE ICD II (13) 2004 186 NYHA II heart failure
Left ventricular EF 35%
QRS duration 130 ms
LVEDD 55 mm
CRT
CONTAK CD (14) 2003 490† NYHA I/IV heart failure
Left ventricular EF 35%
QRS duration 120 ms
CRT
*Of these, 1,438 participants were New York Heart Association (NYHA) functional class II. †Of the
that was responsible for heart failure management and reporting of events were unaware of the a
aware of the assignment; members of the heart failure team, who also assessed the outcome, were
compliance on this request was not reported. §There was an independent outcomes adjudication
were unaware of the treatment assignment; cardiac arrhythmia team was aware of the assignme
CRT  cardiac resynchronization therapy; EF  ejection fraction; ICD  implantable cardiover
Defibrillator Implantation Trial with Cardiac Resynchronization Therapy; MIRACLE ICD II  Multicenter
Ambulatory Heart Failure Trial; REVERSE  Resynchronization Reverses Remodeling in Systolic Left Venimplanted. Four studies performed intention-to-treat anal-
ysis and reported adverse events (10–13) (Table 1). All
studies reported drop-outs.
The 5 clinical trials included a total of 4,317 HF patients
(range 186 to 1,820 patients) with NYHA functional class
I/II symptoms, randomly assigned to CRT (n  2,429)
versus ICD therapy (n  1,888). The pooled baseline
haracteristics are displayed in Table 2. Mean age of the
tudy participants was 65 years. Overall, 80% were male,
0% had ischemic cardiomyopathy, and 9% were asymp-
omatic (NYHA functional class I). At baseline, 97% of
atients were taking angiotensin-converting enzyme inhib-
tors or angiotensin-receptor blockers. However, beta-
lockers were used in 90% of patients in the trials
ublished during or after 2008 (10–12) versus 55% of those
ublished before 2008 (13,14) (Table 2). The baseline
haracteristics of patients assigned to CRT versus ICD
herapy were well balanced in each individual trial (data not
hown).
ortality and HF hospitalization. Mortality and HF
vents or hospitalization data in NYHA I/II functional class
atients were present in all 5 studies (Table 3). Of the 4,317
Design
Follow-Up,
Months Study Quality
Jadad
Score
vs. ICD alone 40 Allocation concealment: adequate
Intention-to-treat: yes
Dropouts reported: yes
Adverse effects reported: yes
Patient and clinicians blinded: yes‡
Outcome assessor blinded: yes‡
5
vs. ICD alone 29 Allocation concealment: adequate
Intention-to-treat: yes
Dropouts reported: yes
Adverse effects reported: yes
Patient and clinicians blinded: no
Outcome assessor blinded: yes§
4
ICD vs. CRT OFFICD 12 Allocation concealment: unclear
Intention-to-treat: yes
Dropouts reported: yes
Adverse effects reported: yes
Patient and clinicians blinded: yes
Outcome assessor blinded: yes§
4
ICD vs. CRT OFFICD 6 Allocation concealment: adequate
Intention-to-treat: yes
Dropouts reported: yes
Adverse effects reported: yes
Patient and clinicians blinded: yes
Outcome assessor blinded: yes
5
ICD vs. CRT OFFICD 6 Allocation concealment: unclear
Intention-to-treat: unclear
Dropouts reported: yes
Adverse effects reported: no
Patient and clinicians blinded: yes
Outcome assessor blinded: yes
4
participants were NYHA I/II. ‡Patients, general health care providers, and the heart failure team
ent; the cardiac arrhythmia team that performed the device implantation and management were
not to obtain chest x-ray films or electrocardiograms on study patients to ensure blinding; however,
tee whose members were unaware of the treatment assignment. Patients and heart failure staff
comes were assessed by the heart failure staff.
brillator; LVEDD  left ventricular end-diastolic dimension; MADIT-CRT  Multicenter AutomaticICD
ICD
ON
ON
ON
se, 263
ssignm
asked
commit
nt; out
ter-defiInSync ICD Randomized Clinical Evaluation II trial; RAFT  Resynchronization/Defibrillation for
tricular Dysfunction Trial.
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died during follow-up. Mortality was lower among patients
assigned to CRT versus ICD (8.0% CRT vs. 11.5% ICD;
RR: 0.81, 95% CI: 0.65 to 0.99; p  0.04; I2  0). Heart
ailure events or hospitalizations were also lower among
atients assigned to CRT (11.6% CRT vs. 18.2% ICD; RR:
.68, 95% CI: 0.59 to 0.79; p  0.001; I2  0). There was
28% reduction in the risk of composite of these outcomes
17.5% CRT vs. 26.4% ICD; RR: 0.72, 95% CI: 0.65 to
.81; p  0.001). Overall, 29 patients needed to be treated
Baseline Characteristics of Asymptomatic or Mildly Symptomatic HTable 2 Baseline Characteristics of Asymptomatic or Mildly Sy
Variable RAFT* MADIT-CRT REVE
N 1,438 1,820 61
Age, yrs 66 65 6
Male, % 83 75 7
Ischemic, % 67 55 5
Atrial fibrillation, % 13 12
Hypertension, % 44 64 5
Diabetes mellitus, % 34 30 2
NYHA functional class I, n 0 265 10
EF, % 23 24 2
LVEDD, mm NR NR 6
LVESD, mm NR NR 5
LVEDV, ml NR 247 26
LVESV, ml NR 177 19
QRS duration, ms 158 158 15
QRS 150 ms, % 58 65 4
LBBB, % 72 71 7
RBBB, % 9 13 1
IVCD, % 12 17 1
Beta-blockers, % 90 93 9
ACE-I/ARB, % 97 98 9
Spironolactone, % 42 32
Digoxin, % 35 26 N
Diuretic, % 84 75 8
Antiarrhythmic drugs, % 16 8 N
*Of the participants in the RAFT trial, 360 (20%) had New York Heart Association (NYHA) function
ACE-I angiotensin-converting enzyme inhibitor; ARB angiotensin-receptor blocker; IVCD in
olume; LVESD  left ventricular end systolic dimension; LVESV  left ventricular end systolic vol
Pooled Mortality and HF Events/HospitalizationAmong Asymptomatic or Mildly Symptomatic PaTable 3 Po led Mortality and HF Events/HoAmong Asymptomatic or Mildly Sym
CRT ICD
NYHA functional class I/II
Mortality 8.0% 11.5%
HF hospitalization 11.6% 18.2%
Combined 17.5% 26.4%
NYHA functional class II
Mortality 9.6% 13.1%
HF hospitalization 14.6% 21.5%
Combined 20.7% 29.3%
NYHA functional class I
Mortality 6.0% 7.1%
HF hospitalization 11.9% 20.5%
Combined 15.5% 22.1%CI  confidence interval; HF  heart failure; NNT  number needed to treat;o prevent 1 death, and 15 needed to be treated to prevent
HF hospitalization (Table 3).
V structure and function. The changes in LV dimensions
nd EF with CRT versus ICD therapy are displayed in
able 4. Mean increase in EF from baseline was 5.9% (95% CI:
.7% to 9.9%) in patients assigned to CRT versus 2.2% (95% CI:
.6% to 2.8%) with ICD (difference CRT vs. ICD 4.1% [95% CI:
.1% to 8.0%]; p  0.001]. Reductions in LV end-diastolic
imensions and volume were significantly greater for patients
ssigned to CRT than for patients assigned to ICD (Table 4).
tients Who Participated in CRT Trialsmatic HF Patients Who Participated in CRT Trials
MIRACLE ICD II CONTAK -CD
Total Weighted
Mean or Frequency
186 263 4,317
63 66 65
89 89 80
57 70 60
0 0 9
NR NR 54
NR NR 30
0 30 402
25 21 24
75 70 70
65 59 59
333 NR 258
256 NR 188
165 158 158
NR NR 58
83 57 72
17 11 11
0 32 16
63 49 88
96 90 97
NR NR 31
NR 67 32
83 82 79
34 NR 10
s III heart failure.
ricular conduction defect; LBBB left bundle branch block; LVEDV left ventricular end diastolic
R  not reported; RBBB  right bundle branch block; other abbreviations as in Table 1.
h CRTs With HFlizations With CRT
atic Patients With HF
RR 95% CI p Value NNT
0.81 0.65–0.99 0.04 29
0.68 0.59–0.79 0.001 15
0.72 0.65–0.81 0.001
0.78 0.65–0.95 0.011 28
0.67 0.57–0.79 0.001 14
0.73 0.64–0.83 0.001
0.85 0.36–2.01 0.71 88
0.57 0.34–0.97 0.04 12
0.70 0.44–1.13 0.14F Pampto
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with NYHA II symptoms. Of these, we were granted access
to subgroup data for 3,412 patients in 4 studies
(10,11,13,14). There was a 22% reduction in mortality
(9.6% CRT vs. 13.1% ICD; RR: 0.78, 95% CI: 0.65 to 0.95;
p  0.01; I2  0) and a 33% reduction in HF events or
ospitalization (14.6% CRT vs. 21.5% ICD; RR: 0.67, 95%
I: 0.57 to 0.79; p  0.001; I2  0) (Table 3).
Asymptomatic (NYHA functional class I) HF patients
n  402) were included in 3 trials (11,12,14). Of these, we
ere granted access to subgroup data for 295 patients in 2
tudies (11,14). There was a 43% reduction in HF hospital-
zation between patients assigned to CRT versus ICD (11.9%
RT vs. 20.5% ICD; RR: 0.57, 95% CI: 0.34 to 0.97; p 
.04). Overall, 12 patients needed to be treated to prevent 1
F hospitalization (Table 3). However, there was no differ-
nce in mortality with CRT among asymptomatic HF patients
6% CRT vs. 20.5% ICD; RR: 0.85, 95% CI: 0.34 to 2.01;
 0.71) (Table 3).
dverse events. Adverse events were reported in 4 studies
ncluding 4,414 patients (10–13). Pooled results are displayed
n Table 5. Overall, 562 (12.7%) patients had an adverse event
elated to device implantation. The majority of these were LV
ead dislodgement and failure to implant the LV lead. Adverse
vents, such as failure to implant, pneumothorax, pocket
ematoma, and infection, were significantly higher among
atients assigned to CRT versus ICD based on data from the
ADIT-CRT (Multicenter Automatic Defibrillator Implan-
ation Trial with Cardiac Resynchronization Therapy) and
AFT (Resynchronization/Defibrillation for Ambulatory
eart Failure) trials in which the patients in the control group
ere not implanted with an LV lead (10,11).
iscussion
n this systematic review of 5 randomized clinical trials
nvolving 4,000 patients with asymptomatic or mildly
ymptomatic HF (NYHA functional class I/II), reduced
Pooled Adverse Events That Occurred Within30 Days of Device Implantation in 4,414 PatientsWith Mild HF Who Particip ed in CRT Trials*
Table 5
Pool d Adverse Eve ts That Occurred Within
30 Days of Device Implantation in 4,414 Patients
With Mild HF Who Participated in CRT Trials*
Total†
n  4,414
CRT‡
n  1,983
ICD‡
n  1,635
In-hospital death 2 (0.04%) 1 (0.05%) 1 (0.06%)
Pneumothorax 48 (1.1%) 30 (1.5%) 14 (0.8%)
Pocket hematoma§ 84 (1.9%) 50 (2.5%) 29 (1.8%)
Pocket infection§ 54 (1.2%) 33 (1.7%) 21 (1.3%)
LV lead dislodgement 182 (7.3%) 101 (5.1%) 0 (0%)
Coronary sinus dissection 22 (0.5%) 16 (0.8%) 0 (0%)
Implant failure 170 (3.9%) 130 (6.6%) 1 (0.1%)
Total 562 (12.7%) 361 (18.2%) 66 (4%)
*The trials that reported adverse events were RAFT, MADIT-CRT, REVERSE, and MIRACLE ICD II.
†Pooled from all 4 trials that reported adverse events. ‡Pooled from the MADIT-CRT and RAFT
trials, which did not implant left ventricle (LV) leads in the control group. §Hematoma or infection
that required intervention.
Abbreviations as in Table 1.EF, and wide QRS complex, CRT was associated with aPo T
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events or hospitalization in comparison with ICD ther-
apy alone. Further, CRT was associated with a significant
improvement in LV dimensions, volume, and EF. These
benefits were robust for patients with NYHA functional
class II symptoms. We also found, for the first time, that
there was a significant reduction in HF events or hospi-
talizations with CRT in asymptomatic HF patients
(NYHA functional class I).
A widened QRS complex on 12-lead electrocardiogra-
phy represents delayed ventricular depolarization, which,
particularly in patients with left bundle branch block,
results in LV dyssynchrony and increased myocardial
strain (19). In patients with myocardial disease, these
findings are associated with abnormal cardiac remodel-
ing, leading to increased LV volume and reduced EF. By
pacing the LV through an electrode positioned in a
coronary vein, CRT creates a more synchronous contrac-
tion with partial restoration of the LV systolic wringing
and twisting motion (20). This improvement in contrac-
tile efficiency with CRT reverses abnormal cardiac re-
modeling, with improvement in cardiac size and function,
and is associated with a reduction in myocardial energy
cost and oxygen consumption (21–23).
Previously, among severely symptomatic HF patients
(NYHA functional class III/IV) with reduced EF and
widened QRS interval, CRT was associated with reverse
remodeling of the LV resulting in improved EF, reduced
LV dimensions and volume, and reduced mitral regurgita-
tion (7,23–25). These structural changes have, in turn, led
to improvement in symptoms, quality of life, and exercise
capacity (4–6,14,25,26). Finally, in large clinical trials,
utilization of CRT and ICD in addition to optimal medical
therapy has resulted in a 39% reduction in HF hospitaliza-
tion and a 36% reduction in mortality in comparison with
ICD alone (8,9).
The present investigation shows that these salutary effects
of CRT also extend to patients with mild HF. Further, to
our knowledge, the present investigation is the first to show
that CRT, in asymptomatic HF patients (NYHA functional
class I) with a low EF and wide QRS interval, was
associated with a significant reduction the risk of hospital-
izations for HF. Previously, in 2 nonrandomized studies,
CRT had led to a degree of improvement in LV volume and
EF in patients with mild HF similar to that in patients with
severe HF, supporting these data (27,28). Further, reverse
cardiac remodeling with improvement in the structure and
function of the LV with angiotensin-converting enzyme
inhibitors was also associated with a reduced mortality and
hospitalization rate in asymptomatic HF patients (29,30).
Thus, cumulatively, these data support the notion that early
administration of CRT delays progression of HF by revers-
ing the LV remodeling process and improves clinical out-
comes. However, potential benefits have to be carefully
weighed against the risk of adverse events associated with
device implantation in these asymptomatic patients.In this meta-analysis, the mortality benefit associated
with CRT among HF patients with NYHA functional class
II symptoms was largely driven by the results of the RAFT
trial (10). Survival curves in the CRT versus ICD arms in
the RAFT study started to diverge after 2.5 years of
follow-up, underscoring the delayed effect of CRT on
mortality. Indeed, the RAFT study had longer follow-up
(average 40 months) than the other trials in this meta-
analysis, including the MADIT-CRT study (average
follow-up 29 months) (Table 1).
Nearly 10% of the patients who participated in the 5
clinical trials that were included in this meta-analysis had
device-related adverse events within 30 days of implanta-
tion. The most common adverse events were failure to
implant the LV lead and LV lead dislodgement. Other
adverse events, such as pneumothorax, pocket hematoma,
and infection, were more likely to occur in patients assigned
to CRT versus ICD. Whether these adverse events were
associated with rehospitalizations were unspecified. Adverse
events related to device implantation should also be taken
into consideration when judging the benefit and cost effec-
tiveness of CRT (31).
Study limitations. The limitations of this systematic re-
view and meta-analysis include the following: The eligibility
criteria of each individual trial included in this meta-analysis
were slightly different from each other (Table 1). However,
the differences were not large enough to prevent pooling of
these study populations. Further, whereas 4 CRT trials
(10,12–14) reported HF hospitalization as an outcome, the
MADIT-CRT trial (11) reported HF events and hospital-
izations, which included outpatient IV treatment of HF.
However, the results did not change when we analyzed the
data including only the HF hospitalizations in the
MADIT-CRT study. Also, we were not granted access to
the data of NYHA functional class I HF patients who
participated in the REVERSE (Resynchronization Reverses
Remodeling in Systolic Left Ventricular Dysfunction) trial
(12). This reduced the number of NYHA functional class I
patients analyzed to 295 from a potential 402, limiting the
power of analysis in this subgroup. Finally, we did not have
the data to separately examine subgroups such as females,
patients with QRS 150 ms, and patients with left bundle
branch block who benefited more from CRT in individual
trials.
Conclusions
This first meta-analysis of randomized clinical trials of CRT
versus ICD demonstrated that CRT improves LV dimen-
sions and reduces mortality and hospitalizations among
asymptomatic or mildly symptomatic HF patients (NYHA
functional class I/II) with reduced EF and widened QRS
complex on electrocardiogram. These benefits were robust
for patients with NYHA functional class II symptoms. We
also found, for the first time, that there was a significant
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asymptomatic HF patients (NYHA functional class I).
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